To evaluate performance of the Minolta JM-103 Jaundice Meter (JM) as a predictor of total serum bilirubin (TSB) in outpatient neonates during the first week postnatal, and to estimate the number of TSB determinations that might be avoided in clinical use.
INTRODUCTION
Several groups have voiced concern regarding an apparent increase in kernicterus, [1] [2] [3] [4] and the American Academy of Pediatrics (AAP) has published a Clinical Practice Guideline that addresses management of hyperbilirubinemia in infants Z35 weeks gestation. 5 Given the reported limitations of visual monitoring, 6 all of these groups emphasize the importance of a more formal approach to monitoring jaundice in neonates. This process is made more difficult by the fact that, for most neonates, total serum bilirubin (TSB) is rising at the time of hospital discharge. 7 The use of a transcutaneous device to estimate TSB may enhance the ability of the clinician to monitor neonates for significant hyperbilirubinemia 8, 9 and some investigators 10, 11 have concluded that use of the BiliCheckt (SpectRx, Inc, Norcross, GA) is an acceptable alternative to laboratory determination of TSB. Others have questioned the accuracy of transcutaneous bilirubin (TcB) measurements, particularly in neonates with relatively high TSB. [12] [13] [14] [15] [16] The majority of studies of TcB have focused on hospitalized neonates prior to peak TSB values. If reliable TcB results could be demonstrated following discharge, when higher TSB values would be anticipated, this rapid, noninvasive, pointof-care technique would be attractive to parents and useful for providers who are implementing the AAP guidelines.
The Minolta/Hill-Rom Air-Shields JM-103 Jaundice Metert (JM; Hatboro, PA) is a refinement of previous transcutaneous models that were considered to have limitations in dark-skinned neonates. 17, 18 Jaundice Meter (JM) has been shown to be in good agreement with TSB in hospitalized term and near-term neonates. 17 However, this device has not been evaluated extensively following newborn hospital discharge; in addition, prior studies have included relatively few Hispanic neonates.
The purpose of this prospective study was to compare TcB values obtained using JM with TSB values in a primarily Hispanic population evaluated following hospital discharge. In addition, we sought to estimate the number of blood tests that might be avoided with typical use of this device.
MATERIALS AND METHODS
The study population consisted of term and near-term neonates who had been discharged from the Newborn Nursery of a large public hospital, Parkland Memorial Hospital in Dallas, Texas, that serves a primarily indigent Hispanic population. 13 Ethnicity is determined by maternal interview, and almost all of the patients' parents are of direct Mexican heritage, based on internal demographic data. Study patients were referred for outpatient follow-up of TSB by the newborn nursery provider because of clinical jaundice prior to hospital discharge, or were jaundiced during outpatient evaluation for another reason (such as provider concern regarding the adequacy of breast feeding). All patients were evaluated during the first week postnatal in a follow-up center located within the nursery. A total of 121 neonates who had not received prior phototherapy were studied between September 2002 and August 2003. None of the parents were instructed prior to discharge to shield their newborns from sunlight. In some instances, patients were evaluated more than once; however, only the initial comparison between JM and TSB is included in this report.
Description of JM
All TcB values were determined by one investigator (MDM) using a single JM device. This JM determines the yellowness of the subcutaneous tissue by measuring the difference in optical densities for light in the blue (450 nm) and green (550 nm) wavelength regions. The device uses a xenon lamp as the light source, and the measuring probe has two optical paths, 18 allowing analysis of light scattered from shallow and deep areas of the subcutaneous tissue. This design feature is intended to minimize the influence of melanin pigment and skin maturity. The device is compact, and its operation is relatively simple. 19 Based on our experience with measurement at different body sites and using varying numbers of determination, we concluded that optimal performance was obtained with a single reading over the sternum (data available on request); preferential use of the sternum site is also in agreement with the results of Maisels et al. (JM) 17 and Poland et al. (BiliCheckt). 20 TcB was measured within 30 minutes of collection of blood for TSB determination.
Blood was drawn by heelstick and TSB determinations were performed in the clinical chemistry laboratory at Parkland. This laboratory performs approximately 5000 total bilirubin assessments per month and utilizes the diazo Jendrassik-Grof with blank method (Olympus AU600, Olympus America Inc., Melville, NY).
Results of the College of American Pathologists Comprehensive Chemistry Proficiency Surveys, C-A 2003 and C-B 2003
, demonstrated that the standard deviation index always was within the acceptable range (bilirubin range 1.6 to 20.2 mg/dl). In a previous study, 13 TSB was measured in 26 samples in our laboratory and by high performance liquid chromatography (HPLC); the largest difference was 1.9 mg/dl, the mean absolute difference was 0.7 mg/dl, and the bias (HPLC result F laboratory result) was 0.5 mg/dl.
Data were analyzed using linear regression and a BlandAltman plot; 21 bias was calculated as the mean of the differences between the paired TSB and JM values. The ability of various JM cutoff values to predict elevated TSB values was analyzed using standard 2 Â 2 table analysis. Sensitivity, specificity, and positive and negative predictive values were calculated. In each instance, the percentage of TSB determinations that might be avoided was calculated [(number of false negatives þ number of true negatives)/total number of comparisons], given the assumption that in clinical practice only neonates with a JM determination greater than a chosen cutoff value (either a true-positive or a falsepositive result) would have a TSB measurement. The AAP Clinical Practice Guideline hour-specific nomogram was used to identify risk zones 5, 22, 23 for bilirubin values during the first week postnatal, TcB and TSB values were plotted, and predictive indices were calculated.
The Institutional Review Board at the University of Texas Southwestern Medical Center at Dallas approved this study, and informed consent was obtained for all neonates.
RESULTS
Demographics of the study population (n ¼ 121) are shown in Table 1 . Median gestational age was 40 weeks in the study neonates; 92% were Hispanic, and 78% were either exclusively or partially breast-fed. TSB values were Z15 mg/dl in 47% of the comparisons. There was a significant correlation between JM and TSB with R ¼ 0.77 (p<0.001), R 2 ¼ 0.59, adjusted R 2 ¼ 0.59, and standard error of estimate ¼ 1.55 mg/dl. The equation for the bestfit line was TSB ¼ 4.94 þ 0.75JM, and F was 170.9 (p<0.001). When non-Hispanic neonates were excluded, R was 0.76 (p<0.001). A weak (R ¼ 0.36, R 2 ¼ 0.13) but significant (p<0.001) correlation between postnatal age and the absolute difference between JM and TSB was noted. A Bland-Altman plot of all 121 comparisons is shown in Figure 1 . The average of JM and TSB values is shown on the x-axis, and the difference is displayed on the y-axis. Since the TSB value is subtracted from the JM determination, a point below the zero line indicates that the TSB for that pair of measurements was greater than JM. TSB was greater than JM in the majority of comparisons, and the bias was À1.6 mg/dl. However, the tendency for JM to underestimate TSB was uniform throughout the range of bilirubin values studied.
Sensitivity, specificity, and positive and negative predictive values for various JM cutoff values and TSB levels ranging from >15 to >18 mg/dl are shown in Table 2 . TSB was >15, >16, >17, and >18 mg/dl in 47, 29, 13, and 9%, respectively. For TSB >17 mg/dl, sensitivity was 1.0 (i.e., no false-negative values were observed) with a JM cutoff value of 13 mg/dl; at this cutoff value, 50% of the TSB determinations would be avoided. For TSB >17 mg/dl and a JM cutoff value of 14 mg/dl, sensitivity was 0.94 (a single false-negative value, with JM ¼ 13.5 mg/dl), and 70% of TSB determinations would be avoided.
The Table 3 . A TSB value in the high-risk zone could be predicted by a JM value in or above the high-intermediate risk zone with a sensitivity of 0.79, and 69% of TSB determinations would be avoided.
SIGNIFICANCE
Renewed concern regarding neonatal jaundice has developed secondary to an apparent rise in the incidence of kernicterus and an increased awareness of the logistical difficulties encountered in monitoring neonates following hospital discharge. Reports describing neonates enrolled in the Pilot Kernicterus Registry 24 indicate that more rigorous follow-up might have prevented devastating consequences in some cases, and several groups have advocated more frequent monitoring of neonates for hyperbilirubinemia. [1] [2] [3] [4] Although visual evaluation of neonates for jaundice is a time-honored method with certain advantages, the disadvantage is that agreement with TSB is poor, even when performed by experienced nursery personnel. The revised AAP guidelines for prevention and management of hyperbilirubinemia emphasize the importance of an objective assessment of bilirubin status for all neonates prior to hospital discharge, and use of a transcutaneous device is considered to be an option for this determination. In addition, the guidelines recommend that during follow-up assessment ''If there is any doubt about the degree of jaundice, the TSB or TcB should be measured. '' 5 Previous studies of TcB have produced conflicting results, with some investigators emphasizing the limitations of this technique, 14 and others reporting that TcB is reliable enough to replace laboratory measurement of TSB entirely. 10, 11 Advances in design technology appear to have improved the reliability of transcutaneous monitoring in the clinical management of neonatal jaundice. Nevertheless, as noted by Rubaltelli et al., 10 it is important to remember that TSB represents a measurement of circulating bilirubin, while TcB is a measurement of tissue bilirubin. Thus, bilirubin distribution may not always be even, and may depend on variables such as rising or falling serum bilirubin. In addition, we observed a weak relationship between postnatal age and the absolute difference between the two methods. Exact numeric equivalence between TSB and TcB may be unattainable by any method.
Prior to introduction of JM, the newest device in widespread use was the BiliCheckt. 25 We reported that in a primarily Hispanic population with relatively high TSBs, the BiliCheckt tended to underestimate TSB, particularly in those neonates with the highest TSB values; 13 other investigators have reported similar findings in primarily non-Hispanic populations. 16 Schumacher 12 noted that this device may be very useful as a screening tool, for example, in evaluating all neonates at 24 hours postnatal, when the majority of neonates will have relatively low TSB. However, he concluded that it may be less useful in neonates with relatively high TSB values.
The Minolta JM-103t is a third-generation Minolta transcutaneous bilirubinometer. In a primarily Caucasian population, Maisels et al. 17 reported that JM provided good agreement with laboratory determination of TSB, with correlations Z0.90. A wide range of TSB values was included; however, most were <13 mg/dl. In the present study, the correlation between JM and TSB (0.77) was lower than reported by Maisels et al.; 17 however, our study population was primarily Hispanic, exclusively postdischarge, and included a higher percentage of neonates with relatively high TSB values (47% were Z15 mg/dl). Because of these differences and given the small number of non-Hispanic neonates in this study, we cannot draw a definitive conclusion regarding any possible influence of ethnicity on JM values. Despite the lower correlation coefficient, we observed no false-negative results when a JM cutoff value of 13 mg/dl was used, and the outcome of interest was a TSB >17 mg/dl. Using these criteria, and assuming that TSB would be obtained only if JM were greater than the cutoff value, the projected TSB determinations could be reduced by 50%. The reduction in estimated TSB determinations increased to 70% when a JM cutoff value of 14 mg/dl was chosen; however, one false-negative value was observed.
Using the BiliCheckt, Bhutani et al. 25 reported that none of the neonates with TSB >95th percentile had a TcB measurement that was less than the 75th percentile (except for one measurement with one of the three devices used). In this study, only 1.1% of the TSB values were >15 mg/dl. Considering the AAP risk zones, 5 which are based on the Bhutani nomogram, 22 we observed a sensitivity of 0.79 when TcB in or above the high-intermediate risk zone was used to predict TSB in the high-risk zone (Table 3) .
Although this study was not a randomized, controlled trial, our results suggest that JM may be useful in the outpatient follow-up of neonates with relatively high TSB values. JM cannot be considered a substitute for laboratory measurement of TSB, but appears to be useful as a screening tool in this population. A significant number of TSB determinations could be avoided with appropriately chosen cutoff values, and this reduction in laboratory evaluation should streamline the follow-up process for families and providers.
